ArticleVirus research2026
Clinical impact of baloxavir-induced PA I38T/M substitutions in diverse influenza populations: a systematic review and meta-analysis.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeasonal influenza imposes substantial clinical and economic burdens, with pediatric populations facing escalating risks of severe complications. While baloxavir marboxil (baloxavir) is an efficacious cap-dependent endonuclease inhibitor, the emergence of treatment-induced PA I38T/M substitutions has raised critical public health concerns. This study aimed to quantify the incidence and clinical consequences of these mutations across diverse populations and explore their mechanistic basis through structural modeling.
methodsA systematic review and meta-analysis of prospective clinical trials was conducted. Primary outcomes included the pooled incidence of mutations and the time to illness alleviation (TTIA). Leave-one-out sensitivity analyses and structural modeling were integrated to evaluate robustness and potential mechanisms.
resultsFive prospective clinical trials comprising pediatric, uncomplicated, and high-risk adult patients were included. The pooled incidence of PA substitutions was 10.5% (95% CI: 0.0% to 21.1%; I
conclusionsPA I38T/M substitutions are associated with noteworthy virological rebound and delayed clinical recovery, predominantly in pediatric populations. These findings emphasize the requirement for age-specific resistance monitoring and support the evaluation of combination antiviral therapies to mitigate resistance emergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.